The Food and Drug Administration recently approved a third drug indicated for treatment of fibromyalgia. Milnacipran, made by Forest Laboratories and Cypres Bioscience, is a selective serotonin and norepinephrine dual reuptake inhibitor. It will be available to consumers in March. The two other medicines approved by the FDA for fibromyalgia are Lyrica, produced by Pfizer, and Cymbalta, produced by Lilly. From my perspective there are at least two remarkable features of these approvals.